GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

31

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

A nuclear protein quality control system for elimination of nucleolus-related inclusions

A nuclear protein quality control system for eliminatio...

88

Bi-allelic variants in WDR47 cause a complex neurodevelopmental syndrome

Bi-allelic variants in WDR47 cause a complex neurodevel...

70

The sequence–structure–function relationship of intrinsic ERα disorder

The sequence–structure–function relationship of intrins...

59